OmniAb, Inc. (OABI)
NASDAQ: OABI · IEX Real-Time Price · USD
4.480
+0.050 (1.13%)
Apr 26, 2024, 4:00 PM EDT - Market closed
OmniAb Revenue
In the year 2023, OmniAb had annual revenue of $34.16M, a decrease of -42.17%. Revenue in the quarter ending December 31, 2023 was $4.82M, a -86.36% decrease year-over-year.
Revenue (ttm)
$34.16M
Revenue Growth
-42.17%
P/S Ratio
15.36
Revenue / Employee
$322,302
Employees
106
Market Cap
524.72M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 34.16M | -24.91M | -42.17% |
Dec 31, 2022 | 59.08M | 24.33M | 70.02% |
Dec 31, 2021 | 34.75M | 11.48M | 49.34% |
Dec 31, 2020 | 23.27M | 4.95M | 27.02% |
Dec 31, 2019 | 18.32M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Phibro Animal Health | 982.01M |
InnovAge Holding | 720.80M |
Valneva SE | 170.79M |
Talkspace | 150.05M |
Calliditas Therapeutics AB (publ) | 119.73M |
IRadimed | 65.56M |
CureVac | 59.73M |
Absci | 5.72M |
OABI News
- 6 days ago - OmniAb to Report First Quarter 2024 Financial Results on May 9 - Business Wire
- 13 days ago - Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics - Accesswire
- 5 weeks ago - OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights - Business Wire
- 2 months ago - OmniAb to Report Fourth Quarter 2023 Financial Results on March 20 - Business Wire
- 2 months ago - OmniAb to Participate in Two Investor Conferences in March - Business Wire
- 4 months ago - OmniAb Presents New Scientific Data on its OmnidAb™ Platform at the 2023 Antibody Engineering & Therapeutics Conference - Business Wire
- 6 months ago - OmniAb Highlights OmnidAb™ Launch and its Expanding Drug Discovery Platform at Today's Research & Technology Virtual Event - Business Wire
- 6 months ago - OmniAb Reports Third Quarter 2023 Financial Results and Business Highlights - Business Wire